John Varga - Concepedia

Author

John Varga

Also Known As

Carter Thorne, Damien Vagner, Evelyn Sutton, J VARGA, J Varga, J. VARGA, J. Varga, JOHN VARGA, John A. Varga, John Varga

457

Publications

32.7K

Citations

H-Index

186

Concepts

All Affiliations

Northwestern University University of Illinois Chicago University of Michigan University of California, Los Angeles University of Pittsburgh

About

John Varga is an author at Northwestern University specializing in medicine, scleroderma, and fibrosis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	50	87	11.1K
2	Public Health	7	7	2.7K
3	Health Sciences	6	6	610
4	Engineering	4	4	310
5	Natural Sciences	1	1	22

John Varga

200

Publications

22.9K

Citations

H-Index

Page 1

	Year	Citations
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension Vallerie V. McLaughlin, Stephen L. Archer, David B. Badesch, Journal of the American College of Cardiology HypertensionPulmonary Arterial HypertensionPulmonary CareCardiovascular DiseasePulmonary Hypertension	2009	2.3K
Cyclophosphamide versus Placebo in Scleroderma Lung Disease Donald P. Tashkin, Robert M. Elashoff, Philip J. Clements, New England Journal of Medicine	2006	1.6K
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial Donald P. Tashkin, Michael D. Roth, Philip J. Clements, The Lancet Respiratory Medicine Sls IiMycophenolate MofetilInflammatory Lung DiseaseAdvanced Lung DiseaseSystemic Scleroderma	2016	1K
Transforming growth factor <i>β</i> (TGF<i>β</i>) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts John Varga, J. Rosenbloom, Sergio A. Jiménez Biochemical Journal Tissue EngineeringHuman GrowthPathologyTgf BetaCell Proliferation	1987	587
Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease Donald P. Tashkin, Robert M. Elashoff, Philip J. Clements, American Journal of Respiratory and Critical Care Medicine	2007	463
Stimulation of Type I Collagen Transcription in Human Skin Fibroblasts by TGF-β: Involvement of Smad 3 Shu-Jen Chen, Weihua Yuan, Yasuji Mori, Journal of Investigative Dermatology Skin DevelopmentFibrosisCutaneous BiologySmad 3Fibroblast Growth Factor	1999	401
Endotrophin triggers adipose tissue fibrosis and metabolic dysfunction Kai Sun, Jiyoung Park, Olga T. Gupta, Nature Communications ObesityMetabolic SyndromeBody CompositionMetabolic DisorderEndotrophin Triggers	2014	356
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial Philip J. Clements, Daniel E. Fürst, Weng Kee Wong, Arthritis & Rheumatism	1999	330
Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities John Varga, Maria Trojanowska, Masataka Kuwana Journal of Scleroderma and Related Disorders SclerostinImmunologyImmune RegulationPathologyDermatology	2017	318
Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: High-dose versus low-dose penicillamine trial Philip J. Clements, Eric L. Hurwitz, Weng Kee Wong, Arthritis & Rheumatism	2000	282

Page 1